HK35397A - Use of hyaluronic acid and forms to prevent arterial restenosis - Google Patents

Use of hyaluronic acid and forms to prevent arterial restenosis Download PDF

Info

Publication number
HK35397A
HK35397A HK35397A HK35397A HK35397A HK 35397 A HK35397 A HK 35397A HK 35397 A HK35397 A HK 35397A HK 35397 A HK35397 A HK 35397A HK 35397 A HK35397 A HK 35397A
Authority
HK
Hong Kong
Prior art keywords
hyaluronic acid
rhamm
component
pharmaceutical composition
composition
Prior art date
Application number
HK35397A
Other languages
German (de)
English (en)
French (fr)
Inventor
Edgar Falk Rudolf
Simon Asculai Samuel
Anne Turley Eva
Original Assignee
Jagotec Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CA1993/000388 external-priority patent/WO1994007505A1/en
Application filed by Jagotec Ag. filed Critical Jagotec Ag.
Publication of HK35397A publication Critical patent/HK35397A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HK35397A 1992-09-25 1997-03-20 Use of hyaluronic acid and forms to prevent arterial restenosis HK35397A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002079205A CA2079205C (en) 1992-09-25 1992-09-25 Use of hyaluronic acid and forms to prevent arterial restenosis
PCT/CA1993/000388 WO1994007505A1 (en) 1991-07-03 1993-09-22 Use of hyaluronic acid and forms to prevent arterial restenosis

Publications (1)

Publication Number Publication Date
HK35397A true HK35397A (en) 1997-03-27

Family

ID=4150463

Family Applications (1)

Application Number Title Priority Date Filing Date
HK35397A HK35397A (en) 1992-09-25 1997-03-20 Use of hyaluronic acid and forms to prevent arterial restenosis

Country Status (26)

Country Link
EP (1) EP0661981B1 (en:Method)
JP (1) JP3742955B2 (en:Method)
CN (1) CN1057908C (en:Method)
AP (1) AP448A (en:Method)
AT (1) ATE141054T1 (en:Method)
AU (1) AU670117B2 (en:Method)
BR (1) BR9307221A (en:Method)
CA (1) CA2079205C (en:Method)
CZ (1) CZ288986B6 (en:Method)
DE (1) DE69303931T2 (en:Method)
DK (1) DK0661981T3 (en:Method)
ES (1) ES2091031T3 (en:Method)
GR (1) GR3021171T3 (en:Method)
HK (1) HK35397A (en:Method)
HU (2) HU227067B1 (en:Method)
IL (1) IL107087A0 (en:Method)
IN (1) IN181289B (en:Method)
MD (1) MD960294A (en:Method)
MX (1) MX9305887A (en:Method)
NO (1) NO309457B1 (en:Method)
NZ (1) NZ255978A (en:Method)
PL (1) PL308201A1 (en:Method)
SG (1) SG48845A1 (en:Method)
SK (1) SK36895A3 (en:Method)
TW (1) TW271401B (en:Method)
ZA (1) ZA937068B (en:Method)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
CA2301018C (en) * 1997-08-22 2006-06-20 Denki Kagaku Kogyo Kabushiki Kaisha Hyaluronic acid gel, method of its production and medical material containing it
FR2813791B1 (fr) 2000-09-14 2004-03-12 Lafon Labor Utilisation de 2- et 4-quinolones pour inhiber la neo-proliferation intimale
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
FR2994846B1 (fr) 2012-08-29 2014-12-26 Vivacy Lab Composition, sterilisee, comprenant au moins un acide hyaluronique et de l'ascorbyl phosphate de magnesium

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease

Also Published As

Publication number Publication date
EP0661981B1 (en) 1996-08-07
BR9307221A (pt) 1999-07-27
AU670117B2 (en) 1996-07-04
HU227067B1 (en) 2010-06-28
SK36895A3 (en) 1997-03-05
NO309457B1 (no) 2001-02-05
MX9305887A (es) 1994-05-31
ATE141054T1 (de) 1996-08-15
JPH08506797A (ja) 1996-07-23
PL308201A1 (en) 1995-07-24
CA2079205C (en) 1998-02-10
GR3021171T3 (en) 1996-12-31
CN1057908C (zh) 2000-11-01
IN181289B (en:Method) 1998-05-02
CZ66295A3 (en) 1996-02-14
ZA937068B (en) 1994-04-18
DE69303931T2 (de) 1997-01-09
EP0661981A1 (en) 1995-07-12
MD960294A (ro) 1997-10-31
SG48845A1 (en) 1998-05-18
NZ255978A (en) 1997-02-24
HU9500857D0 (en) 1995-05-29
NO951122L (no) 1995-03-23
JP3742955B2 (ja) 2006-02-08
HU211698A9 (en) 1995-12-28
IL107087A0 (en) 1993-12-28
AP448A (en) 1996-01-18
AP9300568A0 (en) 1993-10-31
DE69303931D1 (de) 1996-09-12
CZ288986B6 (cs) 2001-10-17
CA2079205A1 (en) 1994-03-26
HUT73637A (en) 1996-08-28
CN1092654A (zh) 1994-09-28
TW271401B (en:Method) 1996-03-01
ES2091031T3 (es) 1996-10-16
AU4812693A (en) 1994-04-26
DK0661981T3 (da) 1996-12-23
NO951122D0 (no) 1995-03-23

Similar Documents

Publication Publication Date Title
US6022866A (en) Use of hyaluronic acid and forms to prevent arterial restenosis
US6852708B2 (en) Use of hyaluronic acid and forms to prevent the narrowing of the vascular walls
WO1994007505A1 (en) Use of hyaluronic acid and forms to prevent arterial restenosis
US5834444A (en) Hyaluronic acid and salts thereof inhibit arterial restenosis
Kang et al. Drug delivery systems for intra-articular treatment of osteoarthritis
Nolte et al. Adenosine inhibits postischemic leukocyte-endothelium interaction in postcapillary venules of the hamster
IL124977A (en) Oral pharmaceutical compositions containing forms of hyaluronic acid for treating restenosis
MX2014003933A (es) Tratamiento de enfermedad de articulacion degenerativa.
EP0661981B1 (en) Use of hyaluronic acid and forms to prevent arterial restenosis
EP2465512A1 (en) Pharmaceutical composition for suppressing pain
Alam et al. Angiostasis and vascular regression in chronic granulomatous inflammation induced by diclofenac in combination with hyaluronan in mice
SK126595A3 (en) Compositions, for inhibition, control and regression of angiogenesis, containing hyaluronic acid and nsaid
AU701014B2 (en) Treatment of disease and conditions associated with macrophage infiltration in particular stroke and myocardial infarction
US20210100832A1 (en) Injectable composition for the treatment of musculoskeletal disorders and methods of use thereof
KR100476782B1 (ko) 히알루론산수용체결합물질과이의용도
AU702929B2 (en) Use of hyaluronic acid and forms to prevent arterial restenosis
CA2120045C (en) Use of hyaluronic acid and forms to prevent arterial restenosis
NZ299942A (en) Use of hyaluronic acid (or fragments thereof) to prevent narrowing of tubular walls in an animal (typically arterial restenosis)
CA2089621A1 (en) Formulations containing hyaluronic acid
CA2106695C (en) Hyaluronic acid and forms to prevent arterial restenosis
JP2667441B2 (ja) 血管内皮細胞増殖抑制剤
JP2000513707A (ja) 投与薬剤の目標化、治療薬および他のグリコサミノグリカン（ｇａｇｓ）
JPH11510515A (ja) 白血球による組織浸潤を阻害するための薬剤
CA3221850A1 (en) Nanoformulations of pazopanib, compositions comprising the same and methods of treating osteoarthritis

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20130921